JP2017518982A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017518982A5 JP2017518982A5 JP2016567865A JP2016567865A JP2017518982A5 JP 2017518982 A5 JP2017518982 A5 JP 2017518982A5 JP 2016567865 A JP2016567865 A JP 2016567865A JP 2016567865 A JP2016567865 A JP 2016567865A JP 2017518982 A5 JP2017518982 A5 JP 2017518982A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- administered
- epiamb
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 206010017533 Fungal infection Diseases 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 1
Claims (8)
-
- 有効量の請求項１に記載のＣ２’ｅｐｉＡｍＢまたはその薬学的に許容される塩を含む、酵母菌または真菌感染を阻害するための薬学的組成物。
- 請求項１に記載のＣ２’ｅｐｉＡｍＢまたはその薬学的に許容される塩を、治療的に有効な量で含む、酵母菌または真菌感染の治療用薬学的組成物。
- 局所投与される、請求項３に記載の薬学的組成物。
- 全身投与される、請求項３に記載の薬学的組成物。
- 経口投与される、請求項３に記載の薬学的組成物。
- 静脈内投与される、請求項３に記載の薬学的組成物。
- 筋肉内投与される、請求項３に記載の薬学的組成物。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461994450P | 2014-05-16 | 2014-05-16 | |
| US61/994,450 | 2014-05-16 | ||
| US201462045907P | 2014-09-04 | 2014-09-04 | |
| US62/045,907 | 2014-09-04 | ||
| PCT/US2015/030965 WO2015175875A1 (en) | 2014-05-16 | 2015-05-15 | Amphotericin b derivative with reduced toxicity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017518982A JP2017518982A (ja) | 2017-07-13 |
| JP2017518982A5 true JP2017518982A5 (ja) | 2018-06-28 |
| JP6543272B2 JP6543272B2 (ja) | 2019-07-10 |
Family
ID=54480735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016567865A Active JP6543272B2 (ja) | 2014-05-16 | 2015-05-15 | 低減された毒性を有するアンホテリシンｂ誘導体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9738677B2 (ja) |
| EP (1) | EP3142672B1 (ja) |
| JP (1) | JP6543272B2 (ja) |
| CA (1) | CA2981288C (ja) |
| DK (1) | DK3142672T3 (ja) |
| ES (1) | ES2749927T3 (ja) |
| WO (1) | WO2015175875A1 (ja) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10087206B2 (en) * | 2014-10-17 | 2018-10-02 | The Board Of Trustees Of The University Of Illinois | Scalable synthesis of reduced toxicity derivative of amphotericin B |
| EP3283171B1 (en) | 2015-04-15 | 2021-05-26 | Sfunga Therapeutics, Inc. | Derivatives of amphotericin b |
| JP7477177B2 (ja) * | 2018-09-07 | 2024-05-01 | ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイ | 毒性が低減されたハイブリッドアムホテリシンｂ誘導体 |
| WO2021026450A1 (en) * | 2019-08-08 | 2021-02-11 | The Board Of Trustees Of The University Of Illinois | Hybrid amphotericin b derivatives with reduced toxicity |
| WO2021030183A1 (en) * | 2019-08-09 | 2021-02-18 | The Board Of Trustees Of The University Of Illinois | Combination treatment of systemic fungal infections |
| WO2024010968A2 (en) * | 2022-07-08 | 2024-01-11 | The Board Of Trustees Of The University Of Illinois | Transfer of c2'-epimerized sugars to the amphotericin b aglycone |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7521418B2 (en) | 2003-05-27 | 2009-04-21 | Theravance, Inc. | Use of a polyene macrolide antifungal agent in combination with a glycopeptide antibacterial agent |
| US8513204B2 (en) | 2004-06-21 | 2013-08-20 | Novartis Ag | Compositions comprising amphotericin B, mehods and systems |
| JP2008503586A (ja) * | 2004-06-21 | 2008-02-07 | ネクター セラピューティクス | アンフォテリシンｂを含む組成物、方法、およびシステム |
| WO2014059436A1 (en) * | 2012-10-12 | 2014-04-17 | The Board Of Trustees Of The University Of Illinois | Electronic tuning of site selectivity |
| US10087206B2 (en) * | 2014-10-17 | 2018-10-02 | The Board Of Trustees Of The University Of Illinois | Scalable synthesis of reduced toxicity derivative of amphotericin B |
-
2015
- 2015-05-15 WO PCT/US2015/030965 patent/WO2015175875A1/en active Application Filing
- 2015-05-15 EP EP15793421.7A patent/EP3142672B1/en active Active
- 2015-05-15 DK DK15793421.7T patent/DK3142672T3/da active
- 2015-05-15 US US15/310,815 patent/US9738677B2/en active Active
- 2015-05-15 CA CA2981288A patent/CA2981288C/en active Active
- 2015-05-15 ES ES15793421T patent/ES2749927T3/es active Active
- 2015-05-15 JP JP2016567865A patent/JP6543272B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017518982A5 (ja) | ||
| JP2017186358A5 (ja) | ||
| JP2014507446A5 (ja) | ||
| JP2017509667A5 (ja) | ||
| JP2017537066A5 (ja) | ||
| JP2019516735A5 (ja) | ||
| JP2016518337A5 (ja) | ||
| JP2015078230A5 (ja) | ||
| JP2017105793A5 (ja) | ||
| EP4252848A3 (en) | Oxysterols and methods of use thereof | |
| JP2013032389A5 (ja) | ||
| JP2018531941A5 (ja) | ||
| JP2018521020A5 (ja) | ||
| JP2012092123A5 (ja) | ||
| JP2014167010A5 (ja) | ||
| CO2018004776A2 (es) | Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana | |
| JP2020097577A5 (ja) | ||
| JP2016532632A5 (ja) | ||
| JP2015516419A5 (ja) | ||
| JP2017505809A5 (ja) | ||
| AR108712A1 (es) | (5r)-5-[3-[(3s)-4-(4-cloro-3-metoxi-5-metil-fenil)-3-metil-piperazin-1-il]-3-oxo-propil]-5-metil-imidazolidin-2,4-diona, composiciones farmacéuticas del mismo para el tratamiento de trastornos inflamatorios y osteoartritis | |
| WO2015125152A3 (en) | Pharmaceutical compositions of asenapine | |
| JP2021191784A5 (ja) | ||
| JP2014148552A5 (ja) | ||
| JP2020527138A5 (ja) |